Barrier identification and strategic design for hypertriglyceridemia management in the post-acute coronary syndrome patient population at a large integrated health system Authors: Zachary M. Salvati, Nicole L. Walters, Andrew Brangan, Benjamin Keiser, Alicia Johns, Stephen J. Voyce, Luciano Kolodny, Sephy Philip, Laney K. Jones, Scott A. LeMaire, Caroline deRichemond Published: 2026 ABSTRACT ObjectivesPatients on statin therapy with persistent hypertriglyceridemia (HTG) (TG > 150 mg/dL) post-acute coronary syndrome (ACS) are at increased risk of residual cardiovascular disease (CVD). Despite recommendations to incorporate icosapent ethyl (IPE) to reduce recurrent CV events, HTG care is not standardized. We aimed to 1) co-design a strategy package to improve CV risk management in post-ACS patients with HTG, and 2) assess TG care changes following the pilot.MethodsA pre-implementation survey assessed clinician perspectives of standardizing HTG management. Contextual inquiries informed a deliberative engagement session to co-design implementation strategies. One cardiology clinic piloted the final package. Resource use and electronic health record data were assessed for outcomes and care patterns.ResultsSurvey responses (N = 16) indicated that a standardized TG management approach is acceptable, appropriate, and feasible. Clinician interviews (N = 7) highlighted lack of priority in HTG care. IPE is favored for CV benefit, but coverage concerns persisted despite established institutional routinization. A strategy package to overcome identified barriers was finalized following deliberative engagement. 50% (20/40) of invited clinicians attended the pilot presentation, and 7.5% used additional resources and workflow strategies. Medication use was consistent among eligible patients, but 1.1% received IPE, limited to severe HTG (>500 mg/dL).ConclusionOperationalized clinician strategies had varied uptake, and IPE use remained minimal. An educational presentation from experts demonstrated importance of intervention but did not translate to clinician motivation. Findings highlight areas for improvement and inform early development of a standardized clinical pathway to reduce CVD risk in post-ACS patients with HTG. Introduction High-intensity statins remain the first-line therapy for patients following acute coronary syndrome (ACS) [1], [2], [3], with the goal of significantly reducing low-density lipoprotein cholesterol (LDL-C) and mitigating recurrent major adverse cardiovascular events (MACE) associated with atherosclerotic cardiovascular disease (ASCVD). However, patients on statin therapy with hypertriglyceridemia (HTG) (≥150 mg/dL) post-ACS are still at an increased residual cardiovascular risk [1], [2], [3]. Factors associated with atherogenic dyslipidemia include HTG, low HDL, and increased abundance of small, dense LDL particles. Isolated atherogenicity of persistent HTG has been noted, especially in mild to moderate cases of HTG [4], [5], [6]. HTG stimulates intimal inflammation, causing endothelial damage from foam cell formation and subsequent atherosclerotic plaque development [2], [3], [4], [5], [6]. Recent data suggest that TG-lowering therapies with proven CV risk reduction are underutilized in patients with HTG [7], [8]. Persistent HTG is a known risk factor for ASCVD [9], [10], and icosapent ethyl (IPE) can be used as a complementary treatment for this high-risk patient population who are already on first-line statin therapies without significant TG reduction [11]. The REDUCE-IT trial [12] highlighted a 25% MACE reduction in this patient population, serving as the primary catalyst for NLA to review the use of IPE for ASCVD risk reduction. The most recent joint statements [13], [14], [15] incorporate guidance similar to European guidelines [16], supporting targeted TG-lowering therapies for post-ACS patients on maximally tolerated statins with persistent HTG. Despite evidence and guidelines to support TG-lowering therapies, caring for these patients is not institutionally standardized [7]. However, optimized care for this population has shown to significantly improve renal outcomes and all-cause mortality [17]. This study sought to improve clinician management of TG post-ACS through a mixed-methods implementation study by 1) designing and iterating an implementation strategy package for a pilot study, and 2) assessing the feasibility of the implementation strategy package in a cardiology practice. Materials and methods Site characteristics Geisinger Health System is an integrated healthcare system serving ~1.2 million people in rural Pennsylvania with more than 26,000 employees, including 1600 employed physicians [18], and 10 hospital campuses across three distinct service areas. Geisinger's Medication Therapy Disease Management (MTDM) program [19] leverages the pharmacotherapy expertise of pharmacists to improve patient health outcomes related to chronic disease management. Human-centered design and implementation strategies Selection of an implementation strategy package and assessing the feasibility of the strategies were completed using aspects of human-centered design (HCD), a methodology used to improve healthcare interventions [20]. HCD studies often incorporate characteristics of empathy-building, user-driven inquiry, ideation, and further refinement through iteration [20], [21]. A portfolio of methods, including a pre-implementation survey, contextual inquiries encompassing site observations and semi-structured interviews, and a deliberative engagement meeting, was conducted to determine clinician readiness, synthesize the current state of post-ACS care in cardiology practices, identify care pathway barriers to HTG management, and tailor selected implementation strategies before pilot launch. This case study research was led by ZS, who chose a social constructivist interpretive framework to better understand the multiple realities constructed from clinician perspectives. Intervention penetration and any changes in post-ACS care were assessed using the electronic health record (EHR) following the pilot. A priori implementation strategies were proposed upon study launch based on preliminary data, providing the study team with time to develop resources for the pilot (Table 1). The proposed strategies, mapped to the Expert Recommendations for Implementing Change (ERIC) [22] are as follows.Table 1Implementation strategies overview (a priori).Name of strategyStudy specific definitionAction targetDevelop and implement tools for quality monitoringElectronic health record tools to order medications, record results, and document care.Service and health outcomes.Develop educational materialsEducation regarding guidelines for post-ACS care.Study team ready to train clinicians on lipid management post-ACS care.Conduct educational outreach visitsEducational materials for post-ACS care are presented to each clinic.Improve knowledge about lipid management post-ACS care.Identify and prepare championsClinical champions.Improved performance of study metrics; reduced costs.Audit and provide feedbackProvide aggregate-level feedback to clinics.Improved effectiveness of care.Study-specific strategies were mapped to the validated Expert Recommendations for Implementing Change (ERIC) strategies to ensure consistent terminology. Action targets represent the intended mechanism or target of the strategy. Table 1Implementation strategies overview (a priori).Name of strategyStudy specific definitionAction targetDevelop and implement tools for quality monitoringElectronic health record tools to order medications, record results, and document care.Service and health outcomes.Develop educational materialsEducation regarding guidelines for post-ACS care.Study team ready to train clinicians on lipid management post-ACS care.Conduct educational outreach visitsEducational materials for post-ACS care are presented to each clinic.Improve knowledge about lipid management post-ACS care.Identify and prepare championsClinical champions.Improved performance of study metrics; reduced costs.Audit and provide feedbackProvide aggregate-level feedback to clinics.Improved effectiveness of care.Study-specific strategies were mapped to the validated Expert Recommendations for Implementing Change (ERIC) strategies to ensure consistent terminology. Action targets represent the intended mechanism or target of the strategy. Implementation strategies overview (a priori). Study-specific strategies were mapped to the validated Expert Recommendations for Implementing Change (ERIC) strategies to ensure consistent terminology. Action targets represent the intended mechanism or target of the strategy. Pre-implementation survey A survey to understand the acceptability, appropriateness, and feasibility of lipid management for post-ACS patients was constructed utilizing open-ended questions and the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) [23]. This validated survey was used to assess readiness for adoption of the implementation strategy package. Geisinger adult cardiology healthcare professionals, including physicians, advanced practice providers, and pharmacists, were invited to participate via email. The survey remained open for four weeks, with one reminder sent after two weeks. Survey respondents were offered a $10 gift card upon completion. Study data were collected and managed using REDCap electronic data capture tools hosted at Geisinger [24]. Descriptive statistics were used to summarize quantitative data. Contextual inquiries Site observations and interviews were conducted to understand the current state of, and potential barriers to, lipid management for post-ACS patients at Geisinger. Geisinger adult cardiology healthcare professionals, including physicians, advanced practice providers, and pharmacists, were invited to participate via email. Participants could choose to complete observation only, interview only, or both. Study staff conducted half-day observations in clinic sites throughout the healthcare system. Clinicians obtained verbal authorization from any patients before allowing study staff to join their appointment per clinical care procedures. Observations were documented using a templated form to capture general notes about the clinic, healthcare professional, and each visit observed, including management options, screening, and medications. Documentation was reviewed to contextualize findings from interviews and surveys. A semi-structured interview guide was created to assess pre-implementation outcomes. Interviews took place virtually following the observation portion of the study, if applicable, and were conducted by study staff (ZS). Demographic questionnaires were completed at the end of each interview. Participants were offered a $50 gift card upon completion of the interview. Interviews were recorded, transcribed verbatim, and de-identified prior to analysis. A codebook guided by Proctor's Conceptual Model of Implementation Research (CMIR) was developed by a study team member with experience in qualitative methods and implementation science (ZS) [25]. The coding team was comprised of two study team members (ZS and NW). A deductive coding approach was used, with each coding team member independently coding one transcript to confirm the presence of CMIR constructs and refine the codebook. The remaining transcripts were split among the coding team for primary coding, followed by review and secondary coding by the other coder. Discrepancies were resolved through discussion among the coding team until consensus was reached [26]. ATLAS.ti (version 8.4.15.0) was used to segment the data by code [27]. Segmented data were reviewed to construct themes for each implementation outcome. Constructed themes were refined through coding team discussion and comparison among the implementation outcomes. Alongside thematic coding, ZS created visual artifacts called process maps [28] to illustrate the current state of treating TG in the post-ACS patient population. These maps served as a baseline to visualize care pathways, helping identify process barriers to overcome and points of intervention to improve upon. Process maps were used to synthesize adoption data, readily conduct cross-case comparisons, and clearly present complex data at the deliberative engagement meeting. Deliberative engagement meeting A deliberative engagement meeting was held with separate clinicians outside of those interviewed to triangulate collected data, ensure generalizability of emerging themes, discuss ideas on how to overcome barriers to post-ACS lipid management, and present the implementation strategies developed by the study team for feedback and refinement. Geisinger healthcare professionals selected by the study team as potential champions were invited to participate via email. A semi-structured guide was created, and the discussion was facilitated by two members of the study team (ZS, CdR). The 60-min virtual meeting was recorded, transcribed verbatim, and de-identified. Participants were offered a $50 gift card upon completion of the meeting. Subsequent analysis of this transcript, partnered with the data analyzed from contextual inquiries, synthesized the main findings in the form of common themes as well as final direction on which elements to prioritize in an implementation strategy package. Qualitative data were analyzed using the same methodology as described for the interviews. Pilot implementation One cardiology clinic at Geisinger was selected to serve as the pilot implementation site. All cardiology healthcare professionals at that site, including physicians, advanced practice providers, and pharmacists, were invited to participate via email. The study team held an educational presentation on the current state of post-ACS care, guideline-based recommendations for hypertriglyceridemia management, and plans for the pilot during a regularly scheduled department meeting, which all healthcare professionals at the clinic were invited to attend. Attendance at the presentation was documented, and the presentation was recorded for those unable to attend. Following the presentation, all healthcare professionals at the pilot clinic received an email to access and download the implementation strategies and complete a baseline survey. The baseline survey consisted of demographics, a question on intent to use the implementation strategy package, and measures from the Implementation Outcomes Questionnaire [29]. Access to the implementation strategies and baseline survey closed two weeks after the educational presentation, and a reminder was sent one week prior to closing. No incentive was provided for completion. Twelve weeks following the launch of the pilot, all healthcare professionals received an invitation to participate in a post-implementation survey via email. The post-implementation survey consisted of demographics, closed- and open-ended questions regarding use of and feedback on the implementation strategy package, and the measures from the Implementation Outcomes Questionnaire to reassess acceptability, feasibility, and appropriateness, and assess penetration of the implementation strategy package [29]. The post-implementation survey was open for two weeks, and a reminder was sent after one week. Following pilot implementation, EHR data pulls were conducted to assess changes in post-ACS hypertriglyceridemia care. Patients with an ACS diagnosis, as defined by ICD-10 codes, who completed an encounter with one of the healthcare professionals at the pilot clinic site during the implementation period, were identified for inclusion. Data included patient demographics, medical history, encounters, laboratory orders and results, and prescriptions for relevant medications before and after the encounter of interest. Analysis was conducted by a biostatistician on the study team (AJ) using SAS Enterprise Guide Version 8.3. Frequencies and percentages were calculated for eligible clinicians who utilized the implementation strategies. Additionally, frequencies and percentages were presented for labs and medications for post-ACS patients who had an encounter with eligible clinicians. The consolidated criteria for reporting qualitative research (COREQ) 32-item checklist [30] guided reporting and ensured validity. This study was designated exempt under Geisinger IRB#2023-1796. Results Pre-implementation survey Pre-implementation readiness for managing TG patients post-ACS (Table 2) was assessed from 16 clinician surveys (10 physicians, 5 nurse practitioners, and 1 pharmacist). Ranging from 1 to 5, the mean AIM score was 3.5 (SD = 1.74), the mean IAM score was 4.0 (SD = 0.76), and the mean FIM score was 4.1 (SD = 0.62), indicating better clinician attitudes towards the appropriateness and feasibility of the intervention as compared to its acceptability.Table 2Pre-implementation readiness survey results.Total (N = 16)Recipient's average AIM score Mean (SD)3.5 (0.74) Median (25th percentile, 75th percentile)3.8 (3.0, 4.0) Minimum, maximum1.5, 4.8Recipient's average IAM score Mean (SD)4.0 (0.76) Median (25th percentile, 75th percentile)4.0 (4.0, 4.0) Minimum, maximum2.0, 5.0Recipient's average FIM score Mean (SD)4.1 (0.62) Median (25th percentile, 75th percentile)4.0 (3.8, 4.5) Minimum, maximum3.0, 5.0Values are presented ranging from 1 (completely disagree) to 5 (completely agree). AIM = Acceptability of Intervention Measure; IAM = Intervention Appropriateness Measure; FIM = Feasibility of Intervention Measure. Table 2Pre-implementation readiness survey results.Total (N = 16)Recipient's average AIM score Mean (SD)3.5 (0.74) Median (25th percentile, 75th percentile)3.8 (3.0, 4.0) Minimum, maximum1.5, 4.8Recipient's average IAM score Mean (SD)4.0 (0.76) Median (25th percentile, 75th percentile)4.0 (4.0, 4.0) Minimum, maximum2.0, 5.0Recipient's average FIM score Mean (SD)4.1 (0.62) Median (25th percentile, 75th percentile)4.0 (3.8, 4.5) Minimum, maximum3.0, 5.0Values are presented ranging from 1 (completely disagree) to 5 (completely agree). AIM = Acceptability of Intervention Measure; IAM = Intervention Appropriateness Measure; FIM = Feasibility of Intervention Measure. Pre-implementation readiness survey results. Values are presented ranging from 1 (completely disagree) to 5 (completely agree). AIM = Acceptability of Intervention Measure; IAM = Intervention Appropriateness Measure; FIM = Feasibility of Intervention Measure. Contextual inquiries Contextual inquiries incorporated both observations and semi-structured interviews with clinician stakeholders. Observational data are seen primarily as supplemental in this study since 17 observations were conducted, but no patients were seen with a history of ACS. Seven interviews were conducted with 3 Physician Assistants (PA-C), 2 Nurse Practitioners (NP), 1 Cardiologist (MD), and 1 Pharmacist (PharmD) with varying levels of experience practicing, but who all had some clinic time scheduled per week (minimum 9–16 h). Five of the 7 clinicians see patients following up with ACS management a few times a week, 1 sees patients in this cohort daily, and 1 sees these patients about once a month. Data visualization artifacts in the form of process maps were constructed to synthesize the current state of treating HTG in the post-ACS patient population. Of the 7 clinicians we interviewed, 3 maps were constructed to showcase different approaches to HTG care pathways for this patient cohort. Interviews revealed distinct care pathways that were stratified by provider type. The Fig. 1 process map highlights an example HTG care pathway for post-ACS patients who were referred to PA-Cs or Cardiologists. Fig. 2 shows the care pathways if these patients are referred to NPs, and Fig. 3 shows the care pathways once these patients meet with a PharmD.Fig. 1Example HTG care pathway — physicians & physician assistants.Example of an HTG care pathway for post-ACS patients referred to PA-Cs and MDs. “MTDM clinic” refers to a Medication Therapy Disease Management (MTDM) of Clinical Lipid Pharmacists assisting in the approval and management of advanced lipid therapies [19].Fig. 1Fig. 2Example HTG care pathway — nurse practitioners.Example of an HTG care pathway for post-ACS patients referred to NPs.Fig. 2Fig. 3Example HTG care pathway — pharmacists.Example of a care pathway for post-ACS patients referred to pharmacists.Fig. 3 Example HTG care pathway — physicians & physician assistants. Example of an HTG care pathway for post-ACS patients referred to PA-Cs and MDs. “MTDM clinic” refers to a Medication Therapy Disease Management (MTDM) of Clinical Lipid Pharmacists assisting in the approval and management of advanced lipid therapies [19]. Example HTG care pathway — nurse practitioners. Example of an HTG care pathway for post-ACS patients referred to NPs. Example HTG care pathway — pharmacists. Example of a care pathway for post-ACS patients referred to pharmacists. Statin therapy was identified as the first-line treatment for this patient population when speaking with the Cardiologist and PA-Cs (Fig. 1), with a greater emphasis on adjusting statin dosage if HTG persists (Table 3).Table 3Patterns identified from clinician interviews and deliberative engagement session.Theme: subtheme(s)Illustrative quote(s)HTG screening and treatment for post-ACS patients are within scope of practice, but targeted therapies are inconsistently adopted.“…usually, I'll see if I can intensify LDL-lowering therapy and address any other factors that could be elevating triglycerides, like alcohol use, diabetes, diet… and then I prefer to intensify LDL-lowering as much as possible and then reassess triglycerides. Obviously, if the triglycerides are very high, like above 1000 or above 500 [mg/dL], then I may…I haven't really encountered that before, so in that case, I may approach it differently. But for the vast majority, triglycerides are usually moderately elevated, like somewhere in the 100 s to 200 [mg/dL] range.” – G05, MD.“I feel like [Cardiologists] generally target LDL and then if LDL is optimized [then] sometimes if…patients come in and they have mildly elevated triglycerides, they're not on specific triglyceride-lowering therapy, so I think we don't use triglyceride-lowering therapy that often, especially [icosapent ethyl]. So, I think there may be room to find patients who would benefit from that.” – G05, MD.In response to a question regarding their first line of therapy for managing hypertriglyceridemia post-ACS: “[Omega-3-acid ethyl esters], typically. It depends on how high it is. If it's, you know, 500 [mg/dL] or less, then typically I just do…over-the-counter fish oil. I've tried to get [omega-3-acid ethyl esters] approved, and I've been running into some issues with that…If it's higher than 500 [mg/dL], then a lot of times I [prescribe] fenofibrates.” – G04, NP.Clinicians are generally in favor of standardizing care related to HTG in patients post-ACS since it's currently decentralized and not prioritized.“I think [standardization is] a great topic to get brought up because like I said, [HTG management] definitely was in the forefront of my mind at one time. It probably has fallen off my radar a bit just because of the busyness of clinic in general. But yeah, I would be excited to receive more education about triglyceride management post-ACS and see what we could do across the system.” – G02, PharmD.“I think [standardization] would be probably a good thing…a lot of times when I see people back who have quite elevated triglycerides, [other clinicians haven't] mentioned them or done anything to treat them, and they kind of just get thrown to the wayside.” – G04, NP.“I think currently [HTG screening] depends on the provider, but I think that [some providers] could be a little lax and not repeat the triglyceride level soon enough, and maybe not be as aggressive with starting medications for them. I know especially like whenever I get patients from primary care providers, they'll be a little bit lax in their levels, and especially with patients post-ACS, I think it's really ideal to get that triglyceride level down to where it needs to be pretty quickly.” – G06, PA-C.Novel HTG medications, particularly icosapent ethyl, are seen as favorable to treat HTG in this patient population, but patient cost and logistics surrounding prior authorization are seen as specific barriers to overcome.“[Icosapent ethyl] is a big buzz. I feel like [our institution] is trying to do a lot around increasing the use of it, which I understand, and I think it's a good thing. So, I almost expected you to ask me that question.” – G02, PharmD.“…I personally would want some kind of standardization for guidance [on HTG management], but the problem is we're sort of limited because so many of those [medications] for triglycerides are cost-prohibitive for our patients and sometimes even theprior [authorizations] don't even work.” – G01, PA-C.“I will say it'll be a hard task because the meds that we love to use for this are expensive…I have a lot of trouble getting [icosapent ethyl] covered for patients. So, I think there's going to be financial barriers to that.” – G03, PA-C.Perceived barriers to implementing a standardized HTG care protocol for post-ACS patients: Elevated LDL-C and managing other comorbidities take precedence.“The priority is…getting blood pressure controlled, getting diabetes controlled, getting heart function back to normal if they've developed a cardiomyopathy. That's gonna be my primary focus, getting the LDL [controlled] first. I mean, all of those things are gonna be my focus first before I go to triglycerides themselves, because I just think it's a time frame where people are worried, they're stressed, they're worried about paying for cardiac rehab, paying for [ticagrelor] that's expensive. So, it's just one of those additional things that I put in the… I, I do, I put it on the back burner until we've handled all the other stuff.” – G03, PA-C.Perceived barriers to implementing a standardized HTG care protocol for post-ACS patients: Lack of clinician awareness regarding the importance of HTG care.“I think the barrier is [clinicians] just maybe not having an awareness of the threshold to really get aggressive with therapy for triglycerides and monitoring triglycerides.” – G01, PA-C.“I see more frequently than not the [Cardiologists] tend not to be as aggressive at treating lipids in general, and they defer to PCPs.” – G04, NP.Perceived barriers to implementing a standardized HTG care protocol for post-ACS patients: Strained resources, including time with patients, alert fatigue, and personnel shortages.“I think some staff may feel overwhelmed already by the number of alerts that come up, so they may be opposed to having another one pop up. I think the other one is there's limited time sometimes in these appointments and if there's an alert that comes up there may be some sense that there's an obligation to discuss it and some clinicians may feel like they're already pushed for time, so I think it could add some some stress to this, to the visit there.” – G05, Cardio MD.“…of course, lipids are important, but they're looking at a lot of other things and so, you know, it may just get brushed over or there's no time to address it. So, I just think while I know it's important, it is really difficult to standardize things and have ‘OK, every single person post ACS goes through this process.’ I have a hard time imagining a process just because of the availability of providers…” – G02, PharmD.“I think that our biggest limitation would be time, just because right now in the clinic especially, we are down a couple of docs we're looking to hire. I think we have two or three positions open for docs and a couple of PA positions, so I feel like right now we're kind short-staffed, so that might be our biggest barrier.” – G06, PA-C.“So, I think a lot of us are, what's the word I want, jaded by the [best practice alerts]. I think they're stupid. Just because it's just always so persistent and lot of times it doesn't really pertain to what's going on, like with our heart failure ones.” – G07, NP.Successful implementation strategies should incorporate provider education and resources to overcome clinician perceptions: An implementation strategy package should incorporate provider education and supplemental resources (the “what”).“...I think it's just education. I mean at least I could speak on our end, you know, when we're told something, we usually are pretty good about working on it… and if it's not like our strong suit or our routine clinical practice, I think we're pretty good about working with each other to figure it out until we become more competent of what the next step would be.” – G07, NP.“…even including a smart phrase that might be like ‘ACS management post MI’ [could help]…” – G07, NP.“I mean I certainly think having the resources of these education meetings where we can certainly review things with triglycerides would be helpful, but I just think for all providers, something in Epic is going to be the most helpful because then it reminds you of the importance of it and addressing it before you leave.” – G01, PA-C.Successful implementation strategies should incorporate provider education and resources to overcome clinician perceptions: Provider education by clinician champions (the “who”).“I think it has to come from the top down and be enforced. So, you know, [Chief of Cardiology], he needs to be an advocate and be on board 100%, but then I think under him, there would need to be like a champion in each region to disseminate the information to their colleagues and talk about the importance and why we're doing it. I think that if it came from like Pharmacy, for example, it wouldn't be well heard…we have a group of providers within the system that are lipid specialists. So, obviously, including them in this process and seeing if they want to be champions in their regions or help with identifying champions across the region…I would say is important.” – G02, PharmD.Successful implementation strategies should incorporate provider education and resources to overcome clinician perceptions: Clinician perceptions of barriers related to prior authorizations and insurance coverage for TG-lowering therapies exist, despite established programs to facilitate (the “why”).“…I feel like again going back to the educational gap and clinical inertia, we as a [redacted] system have, you know, broad systems in place to help with prior authorization to help with cost, but getting the word out there so that clinicians are aware of it aside from MTM… I think it's a big [knowledge] gap, because at [our institution], a clinician could easily prescribe [icosapent ethyl]. If it comes back, it needs a prior authorization… they can send that directly, or the nurse could send that directly to the central med hub team, who can complete the prior authorization. If it's expensive, they can send it directly to our pharmacy reimbursement team. Technically, we don't need an MTM referral to allow that process to happen.” – G08, PharmD.Intervention sustainability relies on shared responsibility across provider types, persistent re-education, and program evaluation.“You know, we have two providers here that do the lipid clinic on certain days of the week, but I mean, they can't absorb all those patients. I think all of us have to have a responsibility for lipids.” – G01, PA-C.“So, I was probably pretty passionate about it when the Reduce-It trial came out because it was new shiny, right? But I feel like since then, we've definitely not done any re-educations. Once in a while I'll read a note where the provider started [icosapent ethyl] on their own, but I would say that's the minority, not the majority. Probably it would be time for like a reeducation, right?” – G02, PharmD.“I don't even know how to say it…that, you know, the pharmacists aren't working up to their license. They're doing things that… they can be doing a lot of other things other than this paperwork for just a prior authorization, so I feel like there's a huge gap from a provider standpoint before getting to put that MTM referral in.” – G11, NP.Quotes to support themes and subthemes constructed from clinician interviews and the deliberative engagement session. MD = Medical Doctor; NP = Nurse Practitioner; PharmD = Pharmacist; PA-C = Physician Assistant. Table 3Patterns identified from clinician interviews and deliberative engagement session.Theme: subtheme(s)Illustrative quote(s)HTG screening and treatment for post-ACS patients are within scope of practice, but targeted therapies are inconsistently adopted.“…usually, I'll see if I can intensify LDL-lowering therapy and address any other factors that could be elevating triglycerides, like alcohol use, diabetes, diet… and then I prefer to intensify LDL-lowering as much as possible and then reassess triglycerides. Obviously, if the triglycerides are very high, like above 1000 or above 500 [mg/dL], then I may…I haven't really encountered that before, so in that case, I may approach it differently. But for the vast majority, triglycerides are usually moderately elevated, like somewhere in the 100 s to 200 [mg/dL] range.” – G05, MD.“I feel like [Cardiologists] generally target LDL and then if LDL is optimized [then] sometimes if…patients come in and they have mildly elevated triglycerides, they're not on specific triglyceride-lowering therapy, so I think we don't use triglyceride-lowering therapy that often, especially [icosapent ethyl]. So, I think there may be room to find patients who would benefit from that.” – G05, MD.In response to a question regarding their first line of therapy for managing hypertriglyceridemia post-ACS: “[Omega-3-acid ethyl esters], typically. It depends on how high it is. If it's, you know, 500 [mg/dL] or less, then typically I just do…over-the-counter fish oil. I've tried to get [omega-3-acid ethyl esters] approved, and I've been running into some issues with that…If it's higher than 500 [mg/dL], then a lot of times I [prescribe] fenofibrates.” – G04, NP.Clinicians are generally in favor of standardizing care related to HTG in patients post-ACS since it's currently decentralized and not prioritized.“I think [standardization is] a great topic to get brought up because like I said, [HTG management] definitely was in the forefront of my mind at one time. It probably has fallen off my radar a bit just because of the busyness of clinic in general. But yeah, I would be excited to receive more education about triglyceride management post-ACS and see what we could do across the system.” – G02, PharmD.“I think [standardization] would be probably a good thing…a lot of times when I see people back who have quite elevated triglycerides, [other clinicians haven't] mentioned them or done anything to treat them, and they kind of just get thrown to the wayside.” – G04, NP.“I think currently [HTG screening] depends on the provider, but I think that [some providers] could be a little lax and not repeat the triglyceride level soon enough, and maybe not be as aggressive with starting medications for them. I know especially like whenever I get patients from primary care providers, they'll be a little bit lax in their levels, and especially with patients post-ACS, I think it's really ideal to get that triglyceride level down to where it needs to be pretty quickly.” – G06, PA-C.Novel HTG medications, particularly icosapent ethyl, are seen as favorable to treat HTG in this patient population, but patient cost and logistics surrounding prior authorization are seen as specific barriers to overcome.“[Icosapent ethyl] is a big buzz. I feel like [our institution] is trying to do a lot around increasing the use of it, which I understand, and I think it's a good thing. So, I almost expected you to ask me that question.” – G02, PharmD.“…I personally would want some kind of standardization for guidance [on HTG management], but the problem is we're sort of limited because so many of those [medications] for triglycerides are cost-prohibitive for our patients and sometimes even theprior [authorizations] don't even work.” – G01, PA-C.“I will say it'll be a hard task because the meds that we love to use for this are expensive…I have a lot of trouble getting [icosapent ethyl] covered for patients. So, I think there's going to be financial barriers to that.” – G03, PA-C.Perceived barriers to implementing a standardized HTG care protocol for post-ACS patients: Elevated LDL-C and managing other comorbidities take precedence.“The priority is…getting blood pressure controlled, getting diabetes controlled, getting heart function back to normal if they've developed a cardiomyopathy. That's gonna be my primary focus, getting the LDL [controlled] first. I mean, all of those things are gonna be my focus first before I go to triglycerides themselves, because I just think it's a time frame where people are worried, they're stressed, they're worried about paying for cardiac rehab, paying for [ticagrelor] that's expensive. So, it's just one of those additional things that I put in the… I, I do, I put it on the back burner until we've handled all the other stuff.” – G03, PA-C.Perceived barriers to implementing a standardized HTG care protocol for post-ACS patients: Lack of clinician awareness regarding the importance of HTG care.“I think the barrier is [clinicians] just maybe not having an awareness of the threshold to really get aggressive with therapy for triglycerides and monitoring triglycerides.” – G01, PA-C.“I see more frequently than not the [Cardiologists] tend not to be as aggressive at treating lipids in general, and they defer to PCPs.” – G04, NP.Perceived barriers to implementing a standardized HTG care protocol for post-ACS patients: Strained resources, including time with patients, alert fatigue, and personnel shortages.“I think some staff may feel overwhelmed already by the number of alerts that come up, so they may be opposed to having another one pop up. I think the other one is there's limited time sometimes in these appointments and if there's an alert that comes up there may be some sense that there's an obligation to discuss it and some clinicians may feel like they're already pushed for time, so I think it could add some some stress to this, to the visit there.” – G05, Cardio MD.“…of course, lipids are important, but they're looking at a lot of other things and so, you know, it may just get brushed over or there's no time to address it. So, I just think while I know it's important, it is really difficult to standardize things and have ‘OK, every single person post ACS goes through this process.’ I have a hard time imagining a process just because of the availability of providers…” – G02, PharmD.“I think that our biggest limitation would be time, just because right now in the clinic especially, we are down a couple of docs we're looking to hire. I think we have two or three positions open for docs and a couple of PA positions, so I feel like right now we're kind short-staffed, so that might be our biggest barrier.” – G06, PA-C.“So, I think a lot of us are, what's the word I want, jaded by the [best practice alerts]. I think they're stupid. Just because it's just always so persistent and lot of times it doesn't really pertain to what's going on, like with our heart failure ones.” – G07, NP.Successful implementation strategies should incorporate provider education and resources to overcome clinician perceptions: An implementation strategy package should incorporate provider education and supplemental resources (the “what”).“...I think it's just education. I mean at least I could speak on our end, you know, when we're told something, we usually are pretty good about working on it… and if it's not like our strong suit or our routine clinical practice, I think we're pretty good about working with each other to figure it out until we become more competent of what the next step would be.” – G07, NP.“…even including a smart phrase that might be like ‘ACS management post MI’ [could help]…” – G07, NP.“I mean I certainly think having the resources of these education meetings where we can certainly review things with triglycerides would be helpful, but I just think for all providers, something in Epic is going to be the most helpful because then it reminds you of the importance of it and addressing it before you leave.” – G01, PA-C.Successful implementation strategies should incorporate provider education and resources to overcome clinician perceptions: Provider education by clinician champions (the “who”).“I think it has to come from the top down and be enforced. So, you know, [Chief of Cardiology], he needs to be an advocate and be on board 100%, but then I think under him, there would need to be like a champion in each region to disseminate the information to their colleagues and talk about the importance and why we're doing it. I think that if it came from like Pharmacy, for example, it wouldn't be well heard…we have a group of providers within the system that are lipid specialists. So, obviously, including them in this process and seeing if they want to be champions in their regions or help with identifying champions across the region…I would say is important.” – G02, PharmD.Successful implementation strategies should incorporate provider education and resources to overcome clinician perceptions: Clinician perceptions of barriers related to prior authorizations and insurance coverage for TG-lowering therapies exist, despite established programs to facilitate (the “why”).“…I feel like again going back to the educational gap and clinical inertia, we as a [redacted] system have, you know, broad systems in place to help with prior authorization to help with cost, but getting the word out there so that clinicians are aware of it aside from MTM… I think it's a big [knowledge] gap, because at [our institution], a clinician could easily prescribe [icosapent ethyl]. If it comes back, it needs a prior authorization… they can send that directly, or the nurse could send that directly to the central med hub team, who can complete the prior authorization. If it's expensive, they can send it directly to our pharmacy reimbursement team. Technically, we don't need an MTM referral to allow that process to happen.” – G08, PharmD.Intervention sustainability relies on shared responsibility across provider types, persistent re-education, and program evaluation.“You know, we have two providers here that do the lipid clinic on certain days of the week, but I mean, they can't absorb all those patients. I think all of us have to have a responsibility for lipids.” – G01, PA-C.“So, I was probably pretty passionate about it when the Reduce-It trial came out because it was new shiny, right? But I feel like since then, we've definitely not done any re-educations. Once in a while I'll read a note where the provider started [icosapent ethyl] on their own, but I would say that's the minority, not the majority. Probably it would be time for like a reeducation, right?” – G02, PharmD.“I don't even know how to say it…that, you know, the pharmacists aren't working up to their license. They're doing things that… they can be doing a lot of other things other than this paperwork for just a prior authorization, so I feel like there's a huge gap from a provider standpoint before getting to put that MTM referral in.” – G11, NP.Quotes to support themes and subthemes constructed from clinician interviews and the deliberative engagement session. MD = Medical Doctor; NP = Nurse Practitioner; PharmD = Pharmacist; PA-C = Physician Assistant. Patterns identified from clinician interviews and deliberative engagement session. Quotes to support themes and subthemes constructed from clinician interviews and the deliberative engagement session. MD = Medical Doctor; NP = Nurse Practitioner; PharmD = Pharmacist; PA-C = Physician Assistant. However, if HTG persists once LDL-C is controlled, icosapent ethyl is considered along with ezetimibe and PCSK9 inhibitors. “I always add statin first and then see where we end up, and then [if] they're not diabetic and we're on high intensity statin and the LDL is well controlled, I typically use [icosapent ethyl].” — G03, PA-C. Still, the Cardiologist communicated that they generally don't use TG-lowering therapies (Table 3). A patient care barrier was noted near the start of the process map as one clinician felt that staff may already feel overwhelmed by the number of alerts, and that limited time in appointments can add to overall stress. Further, there were shared sentiments around TG-lowering medications being costly for patients, and there's perceived difficulty in getting them covered by insurance (Table 3). Alternatively, once patients have an encounter with NPs (Fig. 2), they often prescribe fenofibrates for patients with severe HTG levels >500 mg/dL and consider omega-3-acid ethyl esters or over-the-counter fish oil if TG levels are below that threshold (Table 3). Another NP corroborated the process of starting with fenofibrates and then transitioning to icosapent ethyl. “I'll usually start with fenofibrate just because of affordability, but I do find that [icosapent ethyl] is more efficient…which is what I usually end up getting them on” (G07, NP). That same NP brought up lipid specialist referrals if there's a suspected genetic component and/or if there's persistent HTG >500 mg/dL following medical intervention. “So, if I get to a position where I can't figure out why the triglyceride is still high, like if I think there's a genetic [or] familial component, then I'll refer to our lipid physician.” Prior to the deliberative engagement session, ZS interviewed a PharmD to understand the current state of HTG care in this patient cohort from their perspective (Fig. 3). As suggested by interview data from other clinicians, the PharmD will prescribe icosapent ethyl at this stage if HTG (>150 mg/dL) persists in this patient cohort. When asked about first line of therapy for managing HTG post-ACS, they quickly responded, “Icosapent ethyl, 2 grams, twice a day” and referred to the therapy as a “big buzz” at our institution (Table 3). Alongside data related to the current state of and barriers to HTG care management in the post-ACS patient population (Table 3), preliminary thematic analysis was conducted to understand which implementation strategies should be prioritized in a clinician strategy package for the pilot presentation. Deliberative engagement session Process data from interviews informed a deliberative engagement session with clinical champions (3 PharmDs, 1 NP) and study team members (ZS, CdR, SV, NW, and AB) to help solidify which strategies were both acceptable to incorporate in the implementation strategy package and feasible to implement in a Cardiology practice (Fig. 4).Fig. 4Multi-phased human-centered approach to strategy co-design.The study team employed a multi-phased approach, incorporating feedback and direction from 11 clinicians, to determine the best strategies to include in the final implementation strategy package.Fig. 4 Multi-phased human-centered approach to strategy co-design. The study team employed a multi-phased approach, incorporating feedback and direction from 11 clinicians, to determine the best strategies to include in the final implementation strategy package. All four of the clinical champions reported the presentation by a lipid specialist as a top strategy to promote standardized HTG care for patients post-ACS (Table 4). Presentation slides were seen as a helpful resource that came up for the first time during the deliberative engagement session (Table 4). Another pharmacist (G08, PharmD) corroborated support by making clear, “…the only other thing I was going to add is I think the slides are great.”Table 4Co-developed strategies from the deliberative engagement session.Implementation strategyIllustrative quotePresentation by clinician champion“I think the presentation was very direct and concise, had the most pertinent data and information. Personally, I was very surprised by the underutilization of non-statin triglyceride-lowering therapy, so that was super eye-opening to see. But I think we [established] already a combination of an education gap as far as the significance of elevated triglycerides, [and] also how to treat it… and then overcoming those cost barriers sometimes associated with the preferred therapies. So I think the solution is just filling that educational gap and also making the provider aware of the avenues that we can overcome some of those other barriers.” – G09, PharmD.Pilot presentation slides“I think those slides were really helpful. I even like screenshotted [them]. I know you're gonna share them, but the one that had the percent lowering of each therapy, I was like, ‘oh, that's a good snippet that I just wanna personally have’.” – G10, PharmD.Clinical algorithm“I don't know if it'd be as in depth just because there's not as many therapies, I guess, but I don't think it would be a bad idea because again it's like a quick one page thing that you can reference, and it can maybe even include some of the processes like NP was saying like including the Central Med hub, how to refer to like route your conversation to them or the prior auth team. So maybe it could be like a comprehensive one-pager. I think that's a great idea.” – G10, PharmD.“Top 10 Things to Know” document & smart text for HTG Post-ACS“In all honesty, I like the ‘top 10 things’ for the high triglycerides and I mean not everybody does this… but I have a lot of things that are in a smart text, so if I know I'm seeing somebody with high triglycerides, I make a smart text up and then I just blow it right into my note… so when I'm talking to [patients] or trying to come up with a plan, I have that information right in front of me. I know it's not that simple for a lot of things, but I think [a smart phrase] is very helpful for me so that I'm not missing anything when I'm taking care of patients.” – G11, NP.Quotes to support co-developed strategies from the deliberative engagement session. PharmD = Pharmacist; NP = Nurse Practitioner. Table 4Co-developed strategies from the deliberative engagement session.Implementation strategyIllustrative quotePresentation by clinician champion“I think the presentation was very direct and concise, had the most pertinent data and information. Personally, I was very surprised by the underutilization of non-statin triglyceride-lowering therapy, so that was super eye-opening to see. But I think we [established] already a combination of an education gap as far as the significance of elevated triglycerides, [and] also how to treat it… and then overcoming those cost barriers sometimes associated with the preferred therapies. So I think the solution is just filling that educational gap and also making the provider aware of the avenues that we can overcome some of those other barriers.” – G09, PharmD.Pilot presentation slides“I think those slides were really helpful. I even like screenshotted [them]. I know you're gonna share them, but the one that had the percent lowering of each therapy, I was like, ‘oh, that's a good snippet that I just wanna personally have’.” – G10, PharmD.Clinical algorithm“I don't know if it'd be as in depth just because there's not as many therapies, I guess, but I don't think it would be a bad idea because again it's like a quick one page thing that you can reference, and it can maybe even include some of the processes like NP was saying like including the Central Med hub, how to refer to like route your conversation to them or the prior auth team. So maybe it could be like a comprehensive one-pager. I think that's a great idea.” – G10, PharmD.“Top 10 Things to Know” document & smart text for HTG Post-ACS“In all honesty, I like the ‘top 10 things’ for the high triglycerides and I mean not everybody does this… but I have a lot of things that are in a smart text, so if I know I'm seeing somebody with high triglycerides, I make a smart text up and then I just blow it right into my note… so when I'm talking to [patients] or trying to come up with a plan, I have that information right in front of me. I know it's not that simple for a lot of things, but I think [a smart phrase] is very helpful for me so that I'm not missing anything when I'm taking care of patients.” – G11, NP.Quotes to support co-developed strategies from the deliberative engagement session. PharmD = Pharmacist; NP = Nurse Practitioner. Co-developed strategies from the deliberative engagement session. Quotes to support co-developed strategies from the deliberative engagement session. PharmD = Pharmacist; NP = Nurse Practitioner. Recently, a clinical algorithm was established for LDL-C, and participants mentioned that a similar tool would be helpful for this type of education with triglycerides (Table 4). Suggestions around resource development included the clinical algorithm, as well as a one-page document to know pertinent information regarding HTG management in patients post-ACS. The nurse practitioner liked this strategy, along with a designated smart text for HTG (Table 4). Contextual inquiries revealed mixed perceptions about EHR alerts, and while none of the clinical champions in the deliberative engagement session mentioned this strategy, SV voiced, “I think it's the design of the [Best Practice Alert (BPA)] that matters, and the BPA has to be useful…” Given how this was not mentioned as a top strategy in the deliberative engagement session, and how acceptability was mixed from participants in the contextual interviews, it was determined by the study team that this strategy would have low impact and low feasibility to implement at this time. Strategy development The deliberative engagement session and subsequent thematic analysis revealed the details around preferred implementation strategies (Table 5) that were mapped to the original ERIC [22] strategies to incorporate into the intervention pilot. Six strategies (Fig. 5) were proposed to facilitate clinician education and provide resources in an attempt to standardize TG care management in the post-ACS population, fill any knowledge gaps, and re-prioritize TG care management. The six top strategies were as follows: Presentation by a lipid specialist (pilot presentation), slides from the pilot presentation, a shared recording of the pilot presentation, a “Top 10 Things to Know” document for HTG Post-ACS, a clinical algorithm for treatment of atherogenic HTG lipoprotein remnants, and a shared smart text in the EHR for standard chart language and tracking.Table 5Finalized implementation strategies mapped to ERIC strategies.Name of strategyStudy specific definitionAction targetDetailsDevelop and implement tools for quality monitoringElectronic health record tools to order medications, record results, and document care.Service and health outcomes.Clinician participants felt mixed about EHR alerts but felt that an integrated smart phrase would be both acceptable and feasible.Develop educational materialsEducation regarding guidelines for post-ACS care.Study team ready to train clinicians on lipid management post-ACS care.A clinical algorithm, a “Top 10 Things to Know” document for HTG Post-ACS, presentation slides, and the presentation recording were all seen as helpful to incorporate.Conduct educational outreach visitsEducational materials for post-ACS care are presented to each clinic.Improve knowledge about lipid management post-ACS care.An educational outreach visit or “pilot presentation” was deemed a top strategy to engage clinicians.Identify and prepare championsClinical champions.Improved performance of study metrics; reduced costs.MTDM pharmacists and lipid specialists were seen as clinical champions. Discussed findings in the deliberative engagement session and identified a pharmacy informaticist who could champion cost/prior authorization inertia.Audit and provide feedbackProvide aggregate-level feedback to clinics.Improved effectiveness of care.Study findings have been shared with department leadership.Finalized study-specific strategies and details were adapted from interviews and deliberative engagement sessions and mapped to ERIC taxonomy. Action targets represent the intended mechanism or target of the strategy. ACS = Acute Coronary Syndrome; HTG = Hypertriglyceridemia; EHR = Electronic Health Record; MTDM = Medication Therapy Disease Management.Fig. 5Final co-designed implementation strategy package.Finalized implementation strategies for the intervention pilot following the deliberative engagement session. The six top strategies were categorized as “Clinician Education” and/or “Clinician Resources.”Fig. 5 Table 5Finalized implementation strategies mapped to ERIC strategies.Name of strategyStudy specific definitionAction targetDetailsDevelop and implement tools for quality monitoringElectronic health record tools to order medications, record results, and document care.Service and health outcomes.Clinician participants felt mixed about EHR alerts but felt that an integrated smart phrase would be both acceptable and feasible.Develop educational materialsEducation regarding guidelines for post-ACS care.Study team ready to train clinicians on lipid management post-ACS care.A clinical algorithm, a “Top 10 Things to Know” document for HTG Post-ACS, presentation slides, and the presentation recording were all seen as helpful to incorporate.Conduct educational outreach visitsEducational materials for post-ACS care are presented to each clinic.Improve knowledge about lipid management post-ACS care.An educational outreach visit or “pilot presentation” was deemed a top strategy to engage clinicians.Identify and prepare championsClinical champions.Improved performance of study metrics; reduced costs.MTDM pharmacists and lipid specialists were seen as clinical champions. Discussed findings in the deliberative engagement session and identified a pharmacy informaticist who could champion cost/prior authorization inertia.Audit and provide feedbackProvide aggregate-level feedback to clinics.Improved effectiveness of care.Study findings have been shared with department leadership.Finalized study-specific strategies and details were adapted from interviews and deliberative engagement sessions and mapped to ERIC taxonomy. Action targets represent the intended mechanism or target of the strategy. ACS = Acute Coronary Syndrome; HTG = Hypertriglyceridemia; EHR = Electronic Health Record; MTDM = Medication Therapy Disease Management. Finalized implementation strategies mapped to ERIC strategies. Finalized study-specific strategies and details were adapted from interviews and deliberative engagement sessions and mapped to ERIC taxonomy. Action targets represent the intended mechanism or target of the strategy. ACS = Acute Coronary Syndrome; HTG = Hypertriglyceridemia; EHR = Electronic Health Record; MTDM = Medication Therapy Disease Management. Final co-designed implementation strategy package. Finalized implementation strategies for the intervention pilot following the deliberative engagement session. The six top strategies were categorized as “Clinician Education” and/or “Clinician Resources.” Pilot engagement Department-wide presentations were mentioned in both the contextual inquiries and the deliberative engagement session as a viable strategy to communicate the clinical importance of an initiative and subsequently drive change. The pilot presentation took place on November 12, 2024, during a regional cardiology staff meeting with 50% (20/40) of invited clinicians in attendance. Presentation slides can be found in the supplemental materials, but the content primarily included problems surrounding HTG care in the post-ACS patient population (e.g., “Persistent HTG demonstrates a significant association with recurrent MACE in post-ACS patients, etc.) [7], co-morbidities known to be associated with untreated HTG, known medical therapies, and a call to action to improve outcomes. Pilot outcomes The primary outcome of this intervention was to identify penetration of the implementation strategy package, and the secondary outcome was to assess any changes to post-ACS care management following pilot launch. Following the pilot presentation, clinicians were sent accompanying resources and a baseline survey to determine intent on using the provided resources. 17.5% (7/40) of eligible clinicians completed the baseline survey, and all participants who answered communicated interest in using the provided strategies to help standardize HTG care in the post-ACS patient population. 7.5% (3/40) of eligible clinicians downloaded other implementation strategies, including the “Top 10 Things to Know” document, the clinical algorithm for HTG care, and the associated SmartPhrase, according to REDCap database tracking. None of the eligible clinicians completed the post-intervention survey at the 12-week benchmark. Cross-sectional EHR data pulls over three months showed that of the 176 post-ACS patients with TG values pre- and post-encounter with an eligible clinician, 99.4% (175/176) of eligible patients received medication throughout. Only 1.1% (2/175) of those patients were found to be on IPE. Both patients were noted to have severe HTG (>500 mg/dL) pre-encounter and had no prescription changes pre- and post-encounter with an eligible clinician. Despite the lack of changes in patient health outcomes pre- and post-intervention, the deliberative engagement session and pilot presentation provided opportunities for CdR to meet with department leadership and clinical champions to begin developing a standardized clinical pathway for HTG management in the post-ACS patient population. Discussion This study sought to improve clinician management of TG in the post-ACS patient population through designing and iterating an implementation strategy package for a pilot and assessing the feasibility of the strategy package in a cardiology practice. The suite of mixed methods provided a stepwise approach to curate and iterate on an implementation strategy package that focused primarily on clinician education via presentation from a lipid specialist expert (CdR) and supplemental resources. Prior findings [7] identified the lack of TG-lowering therapies used at the host organization. Study participants corroborated that by communicating a lack of priority to treat HTG as compared to other atherogenicities and comorbid diseases. An implementation strategy package was developed from clinician input following semi-structured interviews and a deliberative engagement session, highlighting a greater emphasis on clinician education through presentations from lipid experts to address clinicians' lack of priority in treating HTG compared to LDL-C and other comorbidities. Literature [31], [32] suggests clinician education via subject matter experts can be one of many interventions to change clinician behavior and support long-term practice changes. Simultaneously, the study team operationalized clinician strategy recommendations by creating and sharing the requested resources. There was modest clinician attendance at the pilot presentation, but minimal penetration of other strategies. There were no significant changes in clinician medication ordering patterns pre- and post-pilot, with minimal IPE use reserved for patients with severe HTG >500 mg/dL. Prior findings [7] showed a similar percentage of patients on IPE (0.8%) with one or more TG-lowering therapies post-ACS between 2015 and 2021, and a recent real-world cohort study in Italy found that patients undergoing cardiac rehabilitation showed a similar lackluster uptake in IPE use due to strict reimbursement guidelines [33]. Clinicians reportedly favor the use of IPE over other TG-lowering therapies due to greater cardiovascular benefit but cited cost and insurance barriers as the main barriers to management. Fenofibrates were seen as a potential alternative to IPE by some clinicians, though evidence to support the cardiovascular benefit of adjunct fibrates to statin-therapy is lacking [34], [35] and can be misrepresented [36]. Despite evidence [10], [13], [37], [38], [39] and backing from professional guidelines [9], [11], [12], [13], [14], [15], [16] to support the supplemental use of IPE following statin therapy for a high-risk patient cohort post-ACS, cost and coverage barriers were cited as reasons why clinicians might opt to start with fenofibrates and non-IPE omega-3, such as over-the-counter fish oil supplements. Cost-utility analyses seen elsewhere [40], [41], [42] have shown the cost-effectiveness of IPE in both primary and secondary prevention settings, but perceived barriers identified from this study show a disconnect between ideal treatments and the current state of managing HTG at a large integrated health system. However, the deliberative engagement session and pilot presentation presented new opportunities for study team members to engage with clinical champions and share this disconnect, leading to prototyping a standardized clinical pathway to reduce CV risk in post-ACS patients with HTG. Limitations This study should be interpreted through the lens of several limitations. This study had a short follow-up window post-intervention at just 12 weeks, limiting our ability to detect gradual changes over time. However, the 3-month assessment gave an early indication that the current strategy package requires further refinement. The low response rate for post-intervention survey completion forced reliance on tracking resource downloads and EHR data pulls rather than self-reported strategy use. Longitudinal data are needed to adequately assess patient outcomes and ensure intervention effectiveness and sustainability. The small sample size and purposive single-site design may limit the transferability to other clinical settings and organizational structures. However, the purpose of this work is to identify local barriers to inform strategy design that are applicable to a specific context rather than establish broad generalizability. The hope is to develop strategy packages that are transferable to other settings, but the clinician cohort with whom we spoke gave detailed approaches to overcoming site-specific barriers. More studies are needed to assess clinician perspectives on the current state of, and noted barriers to, managing cardiovascular risk in post-ACS patients with HTG. Conclusions Perceived barriers to prescribing IPE and lack of priority to managing CV risk in HTG patients were identified as areas to intervene with the implementation strategy package, establishing standardized care pathways for testing and treating HTG post-ACS. Despite operationalizing feedback from clinicians, knowledge obtained from educational sessions did not translate to changed behavior. Implementation strategies were seldom used outside of the pilot clinician education presentation. Rather, this study's primary contribution highlighted specific barriers to post-ACS care and the development of preliminary implementation strategies. This project has mobilized the MTDM clinic pharmacists to create a standardized pathway, and further discussions are underway to iterate the strategy package to feature interactive educational content for clinicians and other digital tools. CRediT authorship contribution statement Zachary M. Salvati: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Data curation. Nicole L. Walters: Writing – review & editing, Writing – original draft, Project administration, Formal analysis, Data curation. Andrew Brangan: Writing – review & editing, Project administration. Benjamin Keiser: Writing – review & editing, Project administration, Investigation. Alicia Johns: Writing – review & editing, Validation, Software, Formal analysis, Data curation. Stephen J. Voyce: Writing – review & editing, Investigation. Luciano Kolodny: Writing – review & editing, Funding acquisition. Sephy Philip: Writing – review & editing, Funding acquisition. Laney K. Jones: Writing – review & editing, Supervision, Methodology, Funding acquisition, Conceptualization. Scott A. LeMaire: Writing – review & editing. Caroline deRichemond: Writing – review & editing, Supervision, Investigation, Conceptualization. Ethics declaration Verbal informed consent to take part in the study and to publish the article was obtained from all participants or their legal representatives. Minimal risk, non-invasive data were collected. This work was approved by Geisinger's Institutional Review Board under approval #2023-1796. Verbal consent was recorded via Microsoft Teams and stored on a secure institutional server. The privacy rights of participants have been observed. This study was performed in compliance with relevant laws, regulatory frameworks and guidelines where the research took place. This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). The Geisinger Institutional Review Board granted an exemption. The authors provided the following explanation: The study is classified as “Exempt - Category 2” since the information obtained is recorded by the investigator in such a manner that the identity of the human participant's cannot readily be ascertained, directly or through identifiers linked to the participants; The study is classified as “Exempt - Category 4” since research involves only information collection and analysis involving the investigator's use of identifiable health information when that use is regulated under 45 CFR parts 160 and 164, subparts A and E, for the purposes of “health care operations” or “research” as those terms are defined at 45 CFR 164.501 or for “public health activities and purposes” as described under 45 CFR 164.512(b). Declaration of Generative AI and AI-assisted technologies in the writing process Institutional AI-assisted technology (M365 Copilot) was used to suggest synonymous wording to meet abstract word count. Funding Amarin Corp. provided the study grant in furtherance of the study. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Zachary Salvati reports financial support was provided by Amarin Pharma Inc. Scott LeMaire reports a relationship with Cerus Corporation that includes: consulting or advisory. Luciano Kolodny reports a relationship with Amarin Pharma Inc. that includes: employment and equity or stocks. Sephy Philip reports a relationship with Amarin Pharma Inc. that includes: employment and equity or stocks. Laney Jones reports a relationship with Amgen Inc. that includes: employment. Caroline deRichemond reports a relationship with Esperion Therapeutics Inc. that includes: board membership. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.